Detalhe da pesquisa
1.
First Approved Kinase Inhibitor for AML.
Cell
; 171(5): 981, 2017 Nov 16.
Artigo
Inglês
| MEDLINE | ID: mdl-29149610
2.
Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy.
Blood
; 142(25): 2192-2197, 2023 12 21.
Artigo
Inglês
| MEDLINE | ID: mdl-37616555
3.
Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
Blood
; 139(24): 3474-3479, 2022 06 16.
Artigo
Inglês
| MEDLINE | ID: mdl-35468180
4.
Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
Br J Haematol
; 202(6): 1127-1136, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37482935
5.
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
Blood
; 137(9): 1196-1207, 2021 03 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32871588
6.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Blood
; 138(21): 2031-2041, 2021 11 25.
Artigo
Inglês
| MEDLINE | ID: mdl-34407542
7.
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
Haematologica
; 108(6): 1567-1578, 2023 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36727397
8.
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.
Haematologica
; 108(9): 2380-2395, 2023 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36951160
9.
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Nature
; 543(7647): 733-737, 2017 03 30.
Artigo
Inglês
| MEDLINE | ID: mdl-28329763
10.
Asciminib for chronic myeloid leukaemia: Next questions.
Br J Haematol
; 199(3): 322-331, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35729850
11.
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
N Engl J Med
; 381(24): 2315-2326, 2019 12 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31826340
12.
Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers.
Haematologica
; 107(2): 358-370, 2022 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34615339
13.
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.
Future Oncol
; 18(38): 4161-4170, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36524980
14.
Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge.
Br J Haematol
; 192(1): 24-27, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33169882
15.
The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.
Br J Cancer
; 122(4): 455-464, 2020 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31792348
16.
Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
Br J Haematol
; 191(3): 433-441, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32352166
17.
TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries.
Br J Haematol
; 190(6): 869-876, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32227648
18.
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
N Engl J Med
; 376(10): 917-927, 2017 03 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28273028
19.
Molecular monitoring in CML: how deep? How often? How should it influence therapy?
Blood
; 132(20): 2125-2133, 2018 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30429156
20.
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.
Blood
; 132(9): 948-961, 2018 08 30.
Artigo
Inglês
| MEDLINE | ID: mdl-29967129